Gene Therapy
REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma
Anticancer Research 2021 October 4 [Link] Kenji Araki, Naoya Yamamuro, Nahoko Tomonobu, Hiromi Kumon Abstract Background/aim: The adenovirus vector- carrying reduced expression in immortalized cell (REIC) gene (Ad-REIC) increases endoplasmic reticulum stress chaperone GRP78/BiP expression and induces the JNK-mediated apoptotic pathway. We aimed to determine whether Ad-REIC-induced apoptotic cell death can trigger immunogenic cell death…
Read MoreTRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared to malignant mesothelioma
Human Pathology 2021 March 2 [Link] Hiroe Itami, Tomomi Fujii, Tokiko Nakai, Maiko Takeda, Yohei Kishi, Fumiaki Taniguchi, Chiyoko Terada, Fumi Okada, Yuji Nitta, Minami Matsuoka, Shoh Sasaki, Sumire Sugimoto, Tomoko Uchiyama, Kohei Morita, Takahiko Kasai, Ryuji Kawaguchi, Chiho Ohbayashi Abstract Adenomatoid tumors (ATs) are benign mesothelial tumors with good prognosis and usually occur in…
Read MoreCorrelation of MTAP Protein Expression with MTAP and CDKN2A Copy Number in Malignant Pleural Mesothelioma
Histopathology 2021 January 2 [Link] David B Chapel, Adrian M Dubuc, Jason L Hornick, Lynette M Sholl Abstract Aims: MTAP immunohistochemistry is a specific marker of CDKN2A deletion in malignant mesothelioma. However, the relationship of MTAP expression with MTAP copy number remains unexplored. Methods and results: Forty malignant pleural mesotheliomas were characterized by targeted next-generation…
Read MoreCorrelation of MTAP Protein Expression with MTAP and CDKN2A Copy Number in Malignant Pleural Mesothelioma
Histopathology 2021 January 2 [Link] David B Chapel, Adrian M Dubuc, Jason L Hornick, Lynette M Sholl Abstract Aims: MTAP immunohistochemistry is a specific marker of CDKN2A deletion in malignant mesothelioma. However, the relationship of MTAP expression with MTAP copy number remains unexplored. Methods and results: Forty malignant pleural mesotheliomas were characterized by targeted next-generation…
Read MoreSomatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma
Clinical Cancer Research 2020 November 17 [Link] Yinfei Tan, Eleonora Sementino, Mitchell Cheung, Suraj Peri, Craig W Menges, Anna-Mariya Kukuyan, Ting Zhang, Vladimir Khazak, Lauren A Fox, Eric A Ross, Suresh Ramanathan, Suresh C Jhanwar, Raja M Flores, Siddharth Balachandran, Joseph R Testa Abstract Purpose: Receptor-interacting protein kinase RIPK3 phosphorylates effector molecule MLKL to trigger…
Read MoreHomozygous deletion of CDKN2A in malignant mesothelioma: Diagnostic utility, patient characteristics and survival in a UK mesothelioma centre
Lung Cancer 2020 November 5 [Link] Kelly Marshall, Susan Jackson, Jennifer Jones, Jayne Holme, Judith Lyons, Emma Barrett, Paul Taylor, Paul Bishop, Clare Hodgson, Michael Green, Nicholas Telford, Matthew Evison Abstract Background: Detection of homozygous deletion of the p16 gene (CDKN2A) by fluorescence in situ hybridization (FISH) has been investigated as an ancillary technique in…
Read MoreIdentification of a Five-Gene Signature for Predicting Survival in Malignant Pleural Mesothelioma Patients
Frontiers in Genetics 2020 August 7 [Link] Yiyang Bai, Xiao Wang, Jia Hou, Luying Geng, Xuan Liang, Zhiping Ruan, Hui Guo, Kejun Nan, Lili Jiang Abstract Malignant pleural mesothelioma (MPM), predominantly caused by asbestos exposure, is a highly aggressive cancer with poor prognosis. The staging systems currently used in clinics is inadequate in evaluating the…
Read MoreBrief Report: Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
Journal of Thoracic Oncology 2019 December 27 [Link] Guo R, DuBoff M, Jayakumaran G, Kris MG, Ladanyi M, Robson ME, Mandelker D, Zauderer MG Abstract INTRODUCTION: Although next-generation sequencing (NGS) has brought insight into critical mutations or pathways (e.g. DNA damage sensing and repair) involved in the etiology of many cancers and directed new screening,…
Read MoreMolecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
International Journal of Molecular Science 2019 November 19 [Link] Belfiore A, Busico A, Bozzi F, Brich S, Dallera E, Conca E, Capone I, Gloghini A, Volpi CC, Cabras AD, Pilotti S, Baratti D, Guaglio M, Deraco M, Kusamura S, Perrone F Abstract Background-There are currently no effective therapies for diffuse malignant peritoneal mesothelioma (DMPM) patients…
Read MoreFirst-ever Abscopal Effect after Palliative Radiotherapy and Immuno-gene Therapy for Malignant Pleural Mesothelioma.
Cureus 2019 February 20 [Link] Barsky AR, Cengel KA, Katz SI, Sterman DH, Simone CB Abstract Malignant pleural mesothelioma (MPM) is a highly aggressive disease, with few, if any, curative interventions. While there is growing interest in using immunotherapy and immuno-gene therapy to treat MPM, very limited data currently exist for combining these modalities with…
Read More